Time to tackle rheumatic heart disease: Data needed to drive global policy dialogues
GLOBAL PUBLIC HEALTH
Authors: Abouzeid, Marian; Wyber, Rosemary; La Vincente, Sophie; Sliwa, Karen; Zuehlke, Liesl; Mayosi, Bongani; Carapetis, Jonathan
Abstract
Rheumatic heart disease (RHD) is an avoidable disease of poverty that persists predominantly in low resource settings and among Indigenous and other high-risk populations in some high-income nations. Following a period of relative global policy inertia on RHD, recent years have seen a resurgence of research, policy and civil society activity to tackle RHD; this has culminated in growing momentum at the highest levels of global health diplomacy to definitively address this disease of disadvantage. RHD is inextricably entangled with the global development agenda, and effective RHD action requires concerted efforts both within and beyond the health policy sphere. This report provides an update on the contemporary global and regional policy landscapes relevant to RHD, and highlights the fundamental importance of good data to inform these policy dialogues, monitor systems responses and ensure that no one is left behind.
A novel bivalent Pasteurellosis-RHD vaccine candidate adjuvanted with Montanide ISA70 protects rabbits from lethal challenge
SAUDI JOURNAL OF BIOLOGICAL SCIENCES
Authors: El-Jakee, Jakeen K.; Moussa, Ihab M.; Omran, Mai S.; Ahmed, Basem M.; Elgamal, Mahmoud A.; Hemeg, Hassan A.; Mubarak, Ayman S.; Al-Maary, Khalid S.; Kabli, Saleh A.; Marouf, Sherif A.; Alhaaji, Jwaher Haji
Abstract
In the present study, a bivalent vaccine against Pasteurella multocida and rabbit hemorrhagic disease virus (RHDV) was formulated with Montanide (TM) ISA70 oil adjuvant (Seppic, Paris, France). Its efficacy was evaluated and compared to similar monovalent preparations and commercially available monovalent vaccines. White new Zeeland rabbit groups (n = 10) received 2 successive doses of the tested vaccines and were challenged 2 weeks after 2nd dose with Pasteurella multocida and RHDV or either pathogens according to their vaccination schedule. Challenged not-vaccinated group of rabbits (n = 10) was included as a control. The bivalent and monovalent ISA70 preparations were found stable, safe, sterile, pure and of low viscosity. Group 3 (GP3) which received bivalent vaccine showed the highest antibody geometric mean titers against Pasteurella multocida and RHDV evaluated by ELISA and hemagglutination inhibition (HI) respectively. Following virulent challenge; Gp3 rabbits were 90% protected from challenge over other groups that showed 80% protection. Detection of either pathogen in the livers of dead and euthanized rabbits had failed except for non-vaccinated controls. The bivalent vaccine candidate was fully protective. Immunization against both pathogens can be achieved by single vaccination. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.